Dominic Cuthbert

French biopharma company Antabio has been awarded up to $8.9 million funding from CARB-X, a public-private partnership devoted to antibacterial R&D. The company was selected...

Eli Lilly and Nektar Therapeutics will, under a new collaboration, co-develop NKTR-358, Nektar’s novel immunological therapy. NKTR-358, which achieved first human dose in Phase 1...

Orchard Therapeutics has picked up a Rare Paediatric Disease Designation for OTL-101, its lead programme for the treatment of ADA-SCID or “bubble baby” disease. OTL-101...